Provided by Tiger Trade Technology Pte. Ltd.

INDIVIOR PLC

35.52
-1.3500-3.66%
Volume:962.12K
Turnover:34.77M
Market Cap:4.19B
PE:12.84
High:36.81
Open:36.53
Low:35.37
Close:36.87
52wk High:42.81
52wk Low:22.22
Shares:118.00M
Float Shares:109.00M
Volume Ratio:0.48
T/O Rate:0.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.77
EPS(LYR):1.64
ROE:12.20%
ROA:26.40%
PB:-20.15
PE(LYR):21.66

Loading ...

Indivior Pharmaceuticals, Inc - Announces Intention to Offer $400 Mln Convertible Senior Notes Due 2031

THOMSON REUTERS
·
Mar 12

Press Release: Indivior Announces Proposed Convertible Senior Notes Offering

Dow Jones
·
Mar 12

Indivior announces findings from real-world evidence from study on Sublocade

TIPRANKS
·
Mar 11

Study links 12-month SUBLOCADE adherence to 42% lower annual non-MOUD medical costs in opioid use disorder

Reuters
·
Mar 11

Indivior Pharmaceuticals Director Barbara Ryan Acquires Common Shares

Reuters
·
Mar 11

Indivior (INDV) Gets a Buy from Northland Securities

TIPRANKS
·
Feb 28

Indivior: Structural Earnings Upgrade and Long-Term Growth Visibility Support Buy Rating

TIPRANKS
·
Feb 27

Indivior Earnings Call: Profits Surge as SUBLOCADE Leads

TIPRANKS
·
Feb 27

Indivior FY 2025 operating income jumps 594% to USD 262 million

Reuters
·
Feb 27

Indivior Pharmaceuticals, Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Feb 27

Sector Update: Health Care

MT Newswires Live
·
Feb 26

Indivior Reports Record 2025 Results, Launches Share Buyback

TIPRANKS
·
Feb 26

Indivior Q4 revenue up 20%, launches $400 mln buyback

Reuters
·
Feb 26

Rpt-Indivior Pharmaceuticals, Inc Outlook FY Revenue USD 1,125-1,195 Million

THOMSON REUTERS
·
Feb 26

Indivior Q4 adjusted EBITDA hits USD 142 million, up 91%

Reuters
·
Feb 26

Indivior Q4 Adj. EPS $0.82 Beats $0.67 Estimate, Sales $358.000M Beat $305.620M Estimate

Benzinga Earnings
·
Feb 26

Indivior Pharmaceuticals, Inc - in 2026, Expect to Deliver Sublocade Dispense Unit Growth in the Mid-Teens

THOMSON REUTERS
·
Feb 26

Indivior Pharmaceuticals, Inc - Authorized New $400 Million Share Repurchase Program

THOMSON REUTERS
·
Feb 26

Indivior Pharmaceuticals, Inc - NOW Executing Phase Ii of Indivior Action Agenda – Accelerate, Which Includes Accelerating Sublocade Throughout 2026

THOMSON REUTERS
·
Feb 26

Indivior Pharmaceuticals to Join Barclays Global Healthcare Conference Fireside Chat

Reuters
·
Feb 24